Bristol To Consider Sales Force Cuts Following Pargluva Delay
This article was originally published in The Pink Sheet Daily
Executive Summary
The setback in development of the diabetes agent also leads Bristol to announce a $500 mil. savings strategy for 2007.
You may also be interested in...
Bristol Looks To Plavix Advertising To Accelerate Product Sales
Acquisitions are one way the company could expand its portfolio ahead of Plavix’ exclusivity loss in 2011, CEO Dolan says.
Bristol Looks To Plavix Advertising To Accelerate Product Sales
Acquisitions are one way the company could expand its portfolio ahead of Plavix’ exclusivity loss in 2011, CEO Dolan says.
Bristol On Track For Growth In 2007 Despite Pargluva Setback
Bristol is reallocating resources toward existing products and aiming to reach growth targets through other pipeline candidates following the delay and possible termination of muraglitazar.